Proactive Investors One2One Forum 26th Manchester

RNS Number : 5435H
e-Therapeutics plc
21 June 2013
 

e-Therapeutics

 

To present at a Proactive Investors One2One Investor Forum in Manchester on Wednesday 26th June 

           

Oxford and Newcastle, UK, 21 June 2013- e-Therapeutics plc (AIM: ETX) announces that Dr Daniel Elger, Chief Financial Officer, will present at a Proactive Investors One2One Forum on Wednesday 26th June in Manchester.

 

The event will take place at the Midland Hotel, Peter Street, Manchester from 6:00pm to 7.30pm, and will be followed by a drinks reception. Further information (including a link to register participation) can be found at: http://www.proactiveinvestors.co.uk/register/event_details/195

 

The event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, analysts and journalists. Dr Elger will be available to speak with participants on an individual basis after the formal presentation.

 

Contacts:

 

e-Therapeutics plc

Daniel Elger

Tel: +44 (0) 7909 915 068

www.etherapeutics.co.uk 

 

Panmure Gordon (UK) Limited

Fred Walsh / Hannah Woodley / Grishma Patel

Tel: +44 (0) 20 7886 2500

www.panmure.com

 

College Hill

Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@collegehill.com

 

 

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery activity is focused in cancer and degenerative diseases of the nervous system and its development effort on clinical candidates for cancer and depression. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGZVNGNGFZM
UK 100

Latest directors dealings